CN109745306B - 9, 10-anthraquinone derivative, preparation method and application thereof - Google Patents
9, 10-anthraquinone derivative, preparation method and application thereof Download PDFInfo
- Publication number
- CN109745306B CN109745306B CN201711075163.6A CN201711075163A CN109745306B CN 109745306 B CN109745306 B CN 109745306B CN 201711075163 A CN201711075163 A CN 201711075163A CN 109745306 B CN109745306 B CN 109745306B
- Authority
- CN
- China
- Prior art keywords
- compound
- anthraquinone derivative
- hcv
- formula
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a 9, 10-anthraquinone derivative, a preparation method and application thereof. The invention provides an application of a 9, 10-anthraquinone derivative shown as a formula I or a pharmaceutically acceptable salt thereof in preparing a medicament for treating and/or preventing hepatitis C; wherein R is R1Substituted C1～C4Alkyl groups of (a); all of R1Independently is-COOR1‑1、‑OH、‑CN、C1～C4Alkyl, or, C1～C4An alkoxy group; all of R1‑1Independently is C1～C4An alkyl group. The 9, 10-anthraquinone derivative provided by the invention shows better anti-HCV activity.
Description
Technical Field
The invention relates to a 9, 10-anthraquinone derivative, a preparation method and application thereof.
Background
Hepatitis c is caused by infection with Hepatitis C Virus (HCV), primarily transmitted from blood/body fluids. According to the world health organization, 1.7 million people are infected with HCV worldwide. The positive rate of anti-HCV of healthy people in China is 0.7-3.1%, and about 3800 ten thousand people. Due to various factors such as the biological characteristics of viruses and the immune function of a host, the immunity of the organism is difficult to effectively eliminate the viruses, so that about 50 to 80 percent of HCV infected persons develop chronic hepatitis, and 20 to 30 percent of the HCV infected persons develop liver cirrhosis. Hepatocellular carcinoma develops in 1-4% of cirrhosis patients each year. Due to the fact that HCV is transmitted by blood and has the characteristics of chronic and secret nature, part of HCV infected persons can develop chronic hepatitis, and serious persons can even develop liver cirrhosis, liver failure or liver cancer (Chinese AIDS, 2017 (5): 461-plus 462; Jilin medical institute, 2017, 38 (2): 123-plus 126).
Physcion (physcion) belonging to anthraquinone is widely present in many plants of Polygonaceae, Leguminosae, Labiatae, Compositae, Orchidaceae and Rosaceae. The physcion has the inhibiting effect on 26 bacteria such as staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, streptococcus, dysentery bacillus and the like; the physcion is a high-activity botanical fungicide and has good control effects on powdery mildew, downy mildew, gray mold, anthracnose and the like. (2015 (4): 938 and 940) in the journal of Chinese materia medica. Patent CN200810203112.1 also discloses that physcion has a certain inhibitory effect on hepatitis c virus, but the effect strength is general, and further structural modification is required to increase activity.
Disclosure of Invention
The invention aims to solve the technical problem of providing a 9, 10-anthraquinone derivative, a preparation method and application thereof. The 9, 10-anthraquinone derivatives show better anti-HCV activity.
The invention provides an application of a 9, 10-anthraquinone derivative shown as a formula I or a pharmaceutically acceptable salt thereof in preparing a medicament for treating and/or preventing hepatitis C;
wherein R is R1Substituted C1～C4Alkyl (said R)1The number of (A) can be one or more, and can also be 1, 2 or 3; when there are more than one R1When there are two arbitrary R1The same or different; said "C1～C4Alkyl of "such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl, and also such as methyl or ethyl; the R is1Substituted C1～C4The alkyl group of (a) may be 2-hydroxyethyl, cyanomethyl or ethoxycarbonylmethyl);
all of R1Independently is-COOR1-1、-OH、-CN、C1～C4Alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl, also e.g. methyl), or, C1～C4Alkoxy (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-butoxy, tert-butoxy, n-butoxy, tert-butoxy, n-butoxy,Isobutoxy or tert-butoxy);
the R is1-1Is C1～C4Alkyl (for example methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl, and also for example ethyl).
In one embodiment, certain groups of compound I are defined as follows, and groups not mentioned are defined as in any of the above embodiments:
r is R1Substituted C1～C4Alkyl groups of (a); all of R1independently-OH or-CN.
The hepatitis c can be HCV type 2a (e.g., caused by the JFH1 strain).
The invention also provides application of the compound I in preparation of HCV inhibitors. Such as HCV type 2a (e.g., caused by the JFH1 strain).
The invention also provides a pharmaceutical composition, which comprises the 9, 10-anthraquinone derivative or the pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used for treating and/or preventing hepatitis C.
The invention also provides a 9, 10-anthraquinone derivative shown as a formula II or a pharmaceutically acceptable salt thereof:
wherein R' is R2Substituted C1～C4Alkyl (said R)2The number of (A) can be one or more, and can also be 1, 2 or 3; when there are more than one R2When there are two arbitrary R2The same or different; said "C1～C4Alkyl groups of "such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl, and also for example methyl);
all of R2Independently is-COOR1-1or-CN;
the above-mentionedR of (A) to (B)1-1Is C1～C4Alkyl (for example methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl, and also for example ethyl).
The R is2Substituted C1～C4The alkyl group of (a) may be cyanomethyl or ethoxycarbonylmethyl.
The invention also provides a preparation method of the compound shown in the formula II, which comprises the following steps: in the presence of alkali, carrying out substitution reaction on a compound 1 (emodin) and a compound 2 to obtain a compound shown in a formula II;
x is halogen.
The halogen can be fluorine, chlorine, bromine or iodine; and may also be chlorine or bromine.
The base may be a base conventional to such reactions in the art, such as an inorganic base (e.g., an alkali metal carbonate, again such as potassium carbonate) and/or an organic base (e.g., an organic amine, again such as triethylamine).
The reaction conditions for the substitution reaction may be those conventional in the art for such reactions, for example the following reaction conditions:
the substitution reaction can be carried out in ketone or ether solvents. The ketone solvent may be a ketone solvent conventional in the reactions of this type in the art, such as acetone; the ethereal solvent may be one conventional in the art for such reactions, such as tetrahydrofuran and/or dioxane. The volume mol ratio of the ketone or ether solvent to the compound 1 can be the volume mol ratio which is conventional in the reaction in the field, such as 3 mL/mmol.
In the substitution reaction, the molar ratio of the compound 2 to the compound 1 can be a molar ratio conventional in the reaction of this type, for example, 2 to 3.
In the substitution reaction, the molar ratio of the compound 2 to the base may be a molar ratio conventional in the art such as 1 to 1.5.
The temperature of the substitution reaction may be any temperature conventional in the art for such reactions, for example, from 0 ℃ to 100 ℃ (e.g., from 45 ℃ to 50 ℃).
The progress of the substitution reaction can be monitored by monitoring methods conventional in the art (e.g., TLC, HPLC, or NMR), and is generally terminated when compound 1 is no longer reacted, and the reaction time can be from 5h to 15h (e.g., 12 h).
The term "pharmaceutically acceptable salt" refers to a salt formed from a suitable non-toxic organic acid, inorganic acid, organic base, or inorganic base and a compound, which retains the biological activity of the compound. The organic acid may be any of various organic acids capable of forming a salt, which are conventional in the art, such as one or more of methanesulfonic acid, p-toluenesulfonic acid, maleic acid, fumaric acid, citric acid, tartaric acid, malic acid, lactic acid, formic acid, acetic acid, propionic acid, trifluoroacetic acid, oxalic acid, succinic acid, benzoic acid, isethionic acid, naphthalenesulfonic acid, and salicylic acid. The inorganic acid may be any of various inorganic acids capable of forming a salt, such as one or more of hydrochloric acid, sulfuric acid, and phosphoric acid, which are conventional in the art. The organic base can be various organic bases which are conventional in the field and can form salts, such as one or more of pyridines, imidazoles, pyrazines, indoles, purines, tertiary amines and anilines. The tertiary amine organic base is triethylamine and/or N, N-diisopropylethylamine. The aniline organic base is, for example, N-dimethylaniline. The pyridine organic base is one or more of pyridine, picoline, 4-dimethylamino pyridine and 2-methyl-5-ethyl pyridine. The inorganic base may be any of various inorganic bases capable of forming a salt, which are conventional in the art, such as one or more of alkali metal hydride, alkali metal hydroxide, alkali metal alkoxide, potassium carbonate, sodium carbonate, lithium carbonate, cesium carbonate, potassium hydrogen carbonate, and sodium hydrogen carbonate. Such as sodium hydride and/or potassium hydride. Such as one or more of sodium hydroxide, potassium hydroxide and lithium hydroxide. The alkoxide of alkali metal is one or more of sodium methoxide, sodium ethoxide, potassium tert-butoxide and sodium tert-butoxide.
On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.
The reagents and starting materials used in the present invention are commercially available.
The positive progress effects of the invention are as follows: the 9, 10-anthraquinone derivative provided by the invention shows better anti-HCV activity.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
Example 1
Dissolving 5mmol of emodin in 15mL of acetone, adding 10mmol of potassium carbonate and 15mmol of chloroacetonitrile, heating to 45 ℃, reacting for 12 hours, decompressing, evaporating the solvent, adding 15mL of water, extracting with 15mL of ethyl acetate for three times, combining organic phases, washing with 15mL of water once, and performing column chromatography (PE/EA-4/1) to obtain the compound 1 with the yield of 59%.
1H NMR(500MHz，CDCl3)δ12.29(s，1H)，11.99(s，1H)，7.65(s，1H)，7.41(d，J＝2.5Hz，1H)，7.11(s，1H)，6.79(d，J＝2.0Hz，1H)，4.91(s，2H)，2.47(s，3H)；13C NMR(126MHz，CDCl3)δ191.1，181.4，164.9，162.7，162.6，149.1，135.8，132.9，124.8，121.6，113.8，113.5，111.9，108.1，107.1，53.3，22.2；ESI-MS：m/z 310.2[M+H]+；307.9[M-H]-。
Example 2
The reaction conditions and operation were the same as in example 1 except that chloroacetonitrile was replaced with ethyl bromoacetate to obtain compound 2 with a yield of 45%.
1H NMR(500MHz，CDCl3)δ12.27(s，1H)，12.05(s，1H)，7.62(s，1H)，7.37(d，J＝2.5Hz，1H)，7.09(s，1H)，6.68(d，J＝2.5Hz，1H)，4.75(s，2H)，4.29(q，J＝2.0Hz，2H)，2.45(s，3H)，1.32(t，J＝7.2Hz，3H)；13C NMR(126MHz，CDCl3)δ190.9，181.7，167.5，164.9，164.5，162.6，148.7，135.4，133.1，124.6，121.4，113.6，111.0，107.9，107.8，65.2，61.8，29.7，22.1，14.1；ESI-MS：m/z 355.0[M-H]-。
Effect examples Activity test for Compounds inhibiting HCV Strain
The purpose is as follows: the antiviral effect of the compound on the HCV2a type JFH1 virus was examined.
The test means is as follows: HCV infection stable cell line Huh7.5.1
Grouping tests: drug positive control (interferon alpha: morri (shanghai) biotechnology limited), drug group compounds to be tested (0, 0.625 μ M, 1.25 μ M, 2.5 μ M, 5 μ M, 10 μ M), negative control group.
Detecting items and indexes: HCV RNA content, nonstructural protein NS3 expression.
The experimental scheme is as follows:
cell: HCV susceptible cell line Huh7.5.1 (Shanghai institute of technology cell Bank), 6-well plate (Corning, USA) cell density, 1 × 105A hole;
virus: JFH1 strain (genotype 2a, institute of Wuhan virus, Chinese academy), with a viral infection count of 1 mol;
the experimental process comprises the following steps:
1. counting cells Huh7.5.1 according to an experimental scheme, then paving the cells in a 6-hole plate, and allowing the cells to adhere to the wall overnight;
2. HCV virus (JFH1) was added at the dose of infection, and after 6 hours of infection, the medium was changed and fresh medium containing derivatives at various concentrations (0, 0.625. mu.M, 1.25. mu.M, 2.5. mu.M, 5. mu.M, 10. mu.M) was added, i.e., serial drug dilutions were established at 2-fold dilutions. And changing fresh culture medium with corresponding concentration according to corresponding concentration every day to maintain the concentration of the medicine. The negative control group of the drug experiment is drug solvent (ddH2O), and the positive control group is interferon (PEG-IFN alpha, 500IU/mL, telaprevir (VX950), 10 μ M).
3. Samples were harvested 72 hours after infection with drug treatment, where the supernatant was TCID50The method detects the titer of infectious virus particles, half of cell components use real-time to detect the copy number of virus genome,half of the virus nonstructural protein NS3 expression levels were measured using the western blot method with GAPDH as a control.
Experimental results form: HCV RNA content, expression of the non-structural protein NS3, viral TCID50And (4) horizontal.
TABLE 1
Claims (9)
1. An application of a 9, 10-anthraquinone derivative shown as a formula I or a pharmaceutically acceptable salt thereof in preparing a medicament for treating and/or preventing hepatitis C;
wherein R is cyanomethyl.
2. The use according to claim 1,
the hepatitis C is HCV type 2 a.
3. A pharmaceutical composition comprising the 9, 10-anthraquinone derivative of formula I or a pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable carrier.
4. Use of a 9, 10-anthraquinone derivative of formula I according to claim 1 for the preparation of an HCV inhibitor.
5. The use according to claim 4, wherein the HCV is HCV type 2 a.
6. A 9, 10-anthraquinone derivative represented by formula II or a pharmaceutically acceptable salt thereof;
wherein R' is cyanomethyl.
7. A process for the preparation of the 9, 10-anthraquinone derivative II according to claim 6, characterized in that it comprises the following steps: carrying out substitution reaction on the compound 1 and the compound 2 in the presence of alkali to obtain the compound shown in the formula II;
x is halogen.
8. The process according to claim 7, wherein the halogen is fluorine, chlorine, bromine or iodine;
and/or, the alkali is alkali metal carbonate and/or organic amine;
and/or, the substitution reaction is carried out in a ketone or ether solvent;
and/or the molar ratio of the compound 2 to the compound 1 is 2-3;
and/or the molar ratio of the compound 2 to the alkali is 1-1.5;
and/or the temperature of the substitution reaction is 0-100 ℃.
9. The method of claim 8, wherein the halogen is chlorine or bromine;
and/or, the alkali metal carbonate is potassium carbonate;
and/or the organic amine is triethylamine;
and/or, the ketone solvent is acetone;
and/or the ether solvent is tetrahydrofuran and/or dioxane;
and/or the temperature of the substitution reaction is 45-50 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711075163.6A CN109745306B (en) | 2017-11-03 | 2017-11-03 | 9, 10-anthraquinone derivative, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711075163.6A CN109745306B (en) | 2017-11-03 | 2017-11-03 | 9, 10-anthraquinone derivative, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109745306A CN109745306A (en) | 2019-05-14 |
| CN109745306B true CN109745306B (en) | 2022-03-22 |
Family
ID=66399450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711075163.6A Active CN109745306B (en) | 2017-11-03 | 2017-11-03 | 9, 10-anthraquinone derivative, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109745306B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114195630B (en) * | 2021-10-26 | 2023-04-25 | 湖南五江高科技材料有限公司 | Synthesis method of photo-curing initiator 9, 10-dialkoxy anthracene |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1515152A (en) * | 2003-08-29 | 2004-07-28 | 湖北省农业科学植保土肥研究所 | Application of antraquinone derivative as pesticide for controlling plant diseases |
| CN101613271A (en) * | 2009-07-28 | 2009-12-30 | 西南大学 | 3-alkoxyl group-6-carboxyl rhein or its pharmacologically acceptable salt and its production and application |
| CN101732293A (en) * | 2008-11-21 | 2010-06-16 | 上海医药工业研究院 | Application of 9,10-anthraquinones |
| US20140335050A1 (en) * | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
| CN104208054A (en) * | 2014-08-27 | 2014-12-17 | 浙江大学 | Application of rheum emodin in preparation of medicine for preventing acute fulminant hepatitis |
| CN105418410A (en) * | 2015-12-21 | 2016-03-23 | 武汉大学 | Emodin derivatives and application thereof in preparation of anti-HIV-1 medicines |
-
2017
- 2017-11-03 CN CN201711075163.6A patent/CN109745306B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1515152A (en) * | 2003-08-29 | 2004-07-28 | 湖北省农业科学植保土肥研究所 | Application of antraquinone derivative as pesticide for controlling plant diseases |
| CN101732293A (en) * | 2008-11-21 | 2010-06-16 | 上海医药工业研究院 | Application of 9,10-anthraquinones |
| CN101613271A (en) * | 2009-07-28 | 2009-12-30 | 西南大学 | 3-alkoxyl group-6-carboxyl rhein or its pharmacologically acceptable salt and its production and application |
| US20140335050A1 (en) * | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
| CN104208054A (en) * | 2014-08-27 | 2014-12-17 | 浙江大学 | Application of rheum emodin in preparation of medicine for preventing acute fulminant hepatitis |
| CN105418410A (en) * | 2015-12-21 | 2016-03-23 | 武汉大学 | Emodin derivatives and application thereof in preparation of anti-HIV-1 medicines |
Non-Patent Citations (3)
| Title |
|---|
| FR-49 EMODIN INHIBITS CELL INVASIVENESS INDUCED BY HCV;B.Buchetti;《Oral Communications / European Journal of Internal Medicine》;20080509;第19S卷;第S42页 * |
| Preparation of novel antiproliferative emodin derivatives and studies on their cellcycle arrest, caspase dependent apoptosis and DNA binding interaction;T.Narender;《Phytomedicine》;20130511;第20卷(第10期);第890-896页 * |
| T.Narender.Preparation of novel antiproliferative emodin derivatives and studies on their cellcycle arrest, caspase dependent apoptosis and DNA binding interaction.《Phytomedicine》.2013,第20卷(第10期),第890-896页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109745306A (en) | 2019-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6598974B2 (en) | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection | |
| CN105473592B (en) | Bi Kabing &#91 for treating virus infection and other diseases;3,2-d]Pyrimidine derivatives | |
| KR100957709B1 (en) | 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus | |
| EP3778608A1 (en) | Polycyclic carbamoylpyridone derivatives, pharmaceutical compositions and use thereof | |
| JP6903658B2 (en) | Heterocyclic indole for use in influenza virus infection | |
| JP4767321B2 (en) | 5,6-Dimethylthieno [2,3-d] pyrimidine derivative, process for producing the same and antiviral pharmaceutical composition containing the same | |
| CN108794487A (en) | Double and ring nucleoid capsid inhibitor and its purposes as drug for treating hepatitis B | |
| CN109745306B (en) | 9, 10-anthraquinone derivative, preparation method and application thereof | |
| CN109748828B (en) | 1, 8-dihydroxy-9, 10-anthraquinone derivative, preparation method and application thereof | |
| CN109745302B (en) | Emodin derivative, preparation method and application thereof | |
| EP2551266A1 (en) | 2',2-dithiazol non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof | |
| CN109265504A (en) | 4- amino acid substitution pyrimidine nucleoside compound and its medicinal usage | |
| US11655268B2 (en) | Nucleoside or nucleotide derivatives, and uses thereof | |
| CN108129366B (en) | Antiviral compounds, methods of preparation and uses thereof | |
| CN109748810B (en) | 2-aminomethyl-9, 10-anthraquinone derivative, preparation method and application thereof | |
| Jiang et al. | Synthesis and antiviral activity of a series of novel N-phenylbenzamide and N-phenylacetophenone compounds as anti-HCV and anti-EV71 agents | |
| CA2790294C (en) | .alpha.-crystalline form of carbabenzpyride | |
| JP5932827B2 (en) | Thiazoleamine derivatives and their use as anti-picornavirus infectious agents | |
| CN104817539B (en) | 2 phenoxyquinoxaline derivatives and its medical usage | |
| CN114805141A (en) | 4-guanidinobenzoic acid aryl ester compound and application thereof in resisting SARS-CoV-2 virus | |
| CN108578410B (en) | Application of octahydro quinazoline-5-one derivative as dengue virus inhibitor | |
| CN113620903A (en) | 4- (benzothiazole-2-yl) -N-substituted aniline compound and preparation method and application thereof | |
| CN103130722B (en) | Novel pyridazine derivative, and preparation method, anti-HIV activity and anti-TMV activity thereof | |
| CN113461623A (en) | Antiviral compound and preparation method and application thereof | |
| CN109415345A (en) | Broad spectrum influenza inhibitor based on pyridazinone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 200040 No. 1320 West Beijing Road, Shanghai, Jingan District Patentee after: Shanghai Pharmaceutical Industry Research Institute Co.,Ltd. Patentee after: China Pharmaceutical Industry Research Institute Co., Ltd Address before: 200040 No. 1320 West Beijing Road, Shanghai, Jingan District Patentee before: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY Patentee before: China Pharmaceutical Industry Research Institute |
|
| CP01 | Change in the name or title of a patent holder |